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Summary 
The potential value of genomic surveillance of nosocomial pathogens for outbreak detection 
and investigation is high but will result in an up-front cost. This early model indicates that 
proactive genomic surveillance of MRSA is likely to be cost effective.  
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ABSTRACT  
Background: Genomic surveillance of MRSA identifies unsuspected transmission events 
and outbreaks.  Used proactively, this could direct early and highly targeted infection control 
interventions to prevent ongoing spread. Here, we evaluate the cost effectiveness of this 
intervention in a model that compared whole genome sequencing plus current practice 
versus current practice alone.  
 
Methods: A UK cost-effectiveness study was conducted using an early model built from the 
perspective of the National Health Service (NHS) and personal social services. 
Effectiveness of sequencing was based on the relative reduction in total MRSA acquisitions 
in a cohort of hospitalised patients in the year following their index admissions. Sensitivity 
analysis was used to illustrate and assess the level of confidence associated with the 
conclusions of our economic evaluation. 
 
Results:  A cohort of 65,000 patients were ran through the model. Assuming that 
sequencing would result in a 90% reduction in MRSA acquisition, 290 new MRSA cases 
were avoided. This gave an absolute reduction of 28.8% and avoidance of two MRSA-
related deaths. Base case results indicated that the use of routine, proactive MRSA 
sequencing would be associated with estimated cost savings of over £728,290 per annual 
hospitalised cohort. The impact in total QALYs was relatively modest, with sequencing 
leading to an additional 14.28 QALYs gained. Results were most sensitive to changes in the 
probability of an MRSA negative patient acquiring MRSA during their hospital admission. 
 
Conclusions: We showed that proactive genomic surveillance of MRSA is likely to be cost-
effective. Further evaluation is required in the context of a prospective study.  
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INTRODUCTION 
Hospital outbreak detection is founded on principles used by John Snow during his 
investigation of a cholera epidemic [1]. Routine surveillance identifies patients who carry or 
are infected with specific pathogens, which is reviewed in relation to patient movement data 
and other information that could link cases. The identification of two or more patients positive 
for the same pathogenic species who are also linked in time and place triggers an 
assessment of the probability of an outbreak. In the case of bacterial pathogens such as 
methicillin-resistant Staphylococcus aureus (MRSA), this assessment may incorporate 
routine data generated by the microbiology laboratory on antibiotic resistance. The pattern of 
resistance to the range of antibiotics tested in the laboratory is used as a surrogate for 
bacterial relatedness, although this lacks sensitivity and specificity. If the initial investigation 
concludes that an outbreak is possible or likely, formal typing methods may be used to 
define bacterial relatedness. Available typing methods lack sensitivity because of their low 
power to discriminate between isolates that reside in the same clone and can erroneously 
link isolates that are not recently related [2-4]. Ultimately, the confirmation of an outbreak is 
based on a combination of imperfect evidence and the intuition of experienced infection 
control staff. 
 
Whole Genome Sequencing (WGS) represents a major advance in the control of multidrug-
resistant organisms (or other organisms) that spread between patients, units and facilities. 
When combined with patient movement data, this provides a more accurate determination of 
transmission events and outbreak status than standard infection control methods alone [2-7]. 
One option for the uptake of bacterial sequencing into clinical practice is to simply swap the 
typing methods used during an outbreak investigation, but there would be several 
advantages of a process redesign in which sequencing was used proactively [8]. This would 
begin with the routine sequencing of specific bacterial species of interest and quantitation of 
genetic relatedness between isolates of the same species. Following sequencing, the 
decision to investigate (or not) would be based on a desk-based analysis of the degree of 
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relatedness combined with information on patient movement.  This model would support 
efficient, highly targeted infection control interventions provided that data can be generated 
rapidly and in a format that does not require specialist informatics knowledge. Early 
evidence for the potential benefits of this ‘Sequence First’ approach comes from a study of 
genomic surveillance of MRSA isolated in a large clinical microbiology laboratory in the East 
of England over 12 months [6]. This led to the identification of hundreds of transmission 
clusters which were not detected by standard infection control. This highlights a missed 
opportunity for greater control through early outbreak detection followed by action to 
minimise on-going transmission.  
 
The potential value of genomic surveillance of nosocomial pathogens is compelling but will 
result in an up-front cost. One rationale to support this cost is to align outbreak detection 
with other types of activity that relate to safety culture, which are fully justified on the basis 
that they save lives through prevention, rapid detection and effective action. However, 
evidence of cost effectiveness is often demanded of changes in healthcare practice.  
 
METHODS 
Model Overview 
The aim of the model was to estimate the cost-effectiveness of whole genome sequencing of 
MRSA combined with standard infection control practice versus standard practice alone. A 
decision tree framework (Figure 1) was used to estimate the reduction in total number of 
MRSA acquisitions (including any subsequent infection), and hence the cost effectiveness of 
whole genome sequencing over one year based on an annual cohort of newly admitted 
hospitalised patients. Patients admitted to hospital or in high risk specialties may be 
screened proactively for carriage of MRSA, with additional MRSA testing occurring when 
clinical samples are taken to investigate patients with clinical features of infection (or as part 
of an outbreak investigation). Patients within the model were classified as either MRSA 
negative (as confirmed by a negative MRSA sample in some cases), MRSA positive 
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asymptomatic (screening swab from a carrier) or MRSA positive infected (isolated from a 
clinical sample).  
 
The model was built from the National Health Service (NHS) and personal social services 
perspective, which is consistent with The National Institute for Health and Care Excellence 
(NICE) reference case [9]. As the model only estimated the cost effectiveness of whole 
genome sequencing within one annual cohort of hospitalised patients, the discounting of 
costs and benefits was not necessary. Per-patient Quality Adjusted Life Years (QALYs) were 
generated and the primary outcome of the model was the incremental cost per QALY 
gained. 
 
Data sources and model parameters 
Classification of Patients 
Data generated during a 12-month prospective observational cohort study between April 
2012 and April 2013 were used to inform patient classification [6]. In brief, the Clinical 
Microbiology and Public Health Laboratory at the Cambridge University Hospitals NHS 
Foundation Trust (CUH) processed samples from consecutive MRSA-positive individuals. 
This facility received samples from three hospitals and 75 GP practices in the East of 
England. A total of 1,465 MRSA-positive patients were identified, and 2,282 MRSA isolates 
underwent whole genome sequencing. For all MRSA-positive cases, epidemiological data 
(including hospital ward stays and residential postcodes) were recorded. The catchment 
area from which the study patients were drawn contained a total of 5,012,137 residents 
according to the 2011 UK Census [6].  
 
Effectiveness Inputs 
The effectiveness of whole genome sequencing was based on the relative reduction in total 
number of MRSA acquisitions that occurred in a cohort of hospitalised patients in the year 
following their index admissions. The number of annual MRSA acquisitions expected within 
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current practice (with data from the 12 month observational cohort study used as a proxy), 
was multiplied by the relative reduction to estimate the reduction in number of MRSA 
acquisitions following whole genome sequencing implementation.  Due to a lack of published 
data to date, the likely size of this relative reduction of MRSA acquisition is hypothetical 
(Table I). The probability of an MRSA negative patient acquiring MRSA whilst in hospital was 
assumed to be 0.5%, in lieu of forthcoming data from an on-going clinical evaluation at 
Cambridge University Hospitals. To explore the implications of these assumptions on the 
cost effectiveness of whole genome screening, both inputs were varied in the sensitivity 
analyses. 
 
MRSA-related mortality 
Within the early model, we assumed that 4.6% of all symptomatic infected MRSA inpatients 
(involving any site or organ) die of MRSA-related causes before hospital discharge (Table I). 
This value came from a retrospective analysis of US National Inpatient Sample data from 
2010 to 2014, where 358,140 MRSA-related hospitalisations were recorded [10]. Consistent 
with the previous literature [11], we assumed that colonised patients with no infection faced 
no MRSA associated mortality risk. 
 
Costs 
We identified only one economic evaluation from a targeted literature search of MRSA 
surveillance and screening strategies in the United Kingdom, which reported the cost of an 
MRSA infected patient when admitted to an intensive care unit [12].  However, they did not 
report the cost of colonisation and we used a Canadian paper as the source for this 
parameter [11]. The paper reported the cost per case of positive asymptomatic MRSA 
colonisation in Canadian Dollars, which was converted into British Pounds using the 
exchange rate in 2010. A unit cost of £100 per genome sequenced was used in the base 
case analysis [4].  The costs to screen a patient for MRSA on admission to hospital, and for 
a clinical sample to be taken to investigate patients with clinical features of infection (as part 
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of an outbreak investigation), were both taken from the NHS Scotland MRSA Screening 
Pathfinder Programme [13] (reported in Robotham et al. [14]).  All unit costs used within the 
economic model were inflated to the 2017/18 price year using the most recent Pay and 
Prices Index within the PSSRU [15], and are presented in Table I.  
 
Health-related Quality of Life (HRQoL) 
We applied a health-related quality of life decrement of 0.35 to patients within the 
symptomatic health state to generate lost quality-adjusted life years (QALYs) (Table 1). As 
MRSA carriage is asymptomatic, it was assumed that there is no QALY decrement 
associated with MRSA positive colonisation without infection.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
 
Sensitivity Analysis 
Sensitivity analysis was used to illustrate and assess the level of confidence associated with 
the conclusions of our economic evaluation. Both one-way (where input parameters are 
varied one by one between plausible extremes) and two-way (where more than one 
parameter is varied at the same time) sensitivity analyses were conducted to assess the 
robustness of the overall results within the model and to quantify effects of uncertainty on 
the cost-effectiveness of whole genome sequencing.  
 
RESULTS 
Clinical outcomes  
The clinical outcomes estimated within the early model are presented in Table 2. A cohort of 
65,000 patients were ran through the model (equating to the estimated number of annual 
admissions for Addenbrooke’s hospital between April 2012 and April 2013) [6]. Under the 
assumption that data from whole genome sequencing would result in a 90% reduction in 
MRSA acquisition, 290 new MRSA cases were avoided (which includes asymptomatic 
carriage and clinical infection). This gave an absolute reduction of 28.8% and an avoidance 
of two MRSA-related deaths. 
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Economic outcomes 
Our base case results indicated that the use of routine, proactive MRSA sequencing would 
be associated with estimated cost savings of over £728,290 per annual hospitalised cohort 
(Table 3). The difference in total QALYs between the two patient cohorts was more modest, 
with sequencing leading to an additional 14.28 QALYs gained. The results were most 
sensitive to changes in the probability of an MRSA negative patient acquiring MRSA during 
their hospital admission. The results were also sensitive to the proportion of MRSA positive 
patients with clinical infection at the time of presentation to hospital, and the relative 
reduction in cases of MRSA acquisition due to actions taken in response to whole genome 
sequencing data. Figure 2 presents threshold graphs, illustrating the change in incremental 
costs and MRSA carriage and clinical infection events avoided as these parameters are 
changed. The higher the probability of an MRSA negative patient acquiring MRSA during 
their stay, the greater the MRSA events avoided and the more costs saved by MRSA 
sequencing. A greater cost saving was observed as the relative reduction in MRSA 
acquisitions due to the implementation of sequencing increased. See the supplementary 
material for further sensitivity analysis. 
 
The two-way sensitivity analysis presented in Figure 3 provides an overview of how the 
ICER changes when the key drivers of the cost-effectiveness results are varied 
simultaneously. Whole genome sequencing was estimated to be cost-effective in the 
majority of scenarios that have been presented. For example, sequencing was expected to 
be cost-effective as long as the effectiveness was over 30%, regardless of the probability 
that a MRSA negative patient would acquire MRSA during their hospital admission. The 
effectiveness could drop to 10% and sequencing is still expected to be cost-effective as long 
as the probability that a MRSA negative patient would acquire MRSA during their hospital 
admission was over 0.4%. 
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DISCUSSION 
Our model is the first to estimate the cost-effectiveness of routine whole genome sequencing 
of MRSA as an infection control tool. This indicated that routine MRSA sequencing would 
result in fewer MRSA cases (both carriage and clinical infection involving any organ or body 
site), and have a small positive impact on HRQoL on a per-patient basis (regardless of 
whether they have, or are tested for MRSA). This technological application is also likely to 
be cost saving assuming the relative reduction in MRSA cases is 90%. Given this 
assumption, extensive sensitivity analyses supported our cost-saving conclusion, even with 
large reductions in key parameters.   
 
MRSA screening policies, prevalence of MRSA, patient characteristics and infection control 
practices may vary between different hospitals in England, which limits the generalisability of 
the results. Despite this, sequencing remained cost-effective when this value was varied in a 
sensitivity analysis.  It must also be noted that the cost-effectiveness of sequencing is 
dependent upon the prevalence of MRSA colonization in patients upon admission to 
hospital. A greater prevalence allows for a larger potential for the reduction in MRSA 
transmission, and hence a greater benefit associated with sequencing. 
 
Our analyses represent an early, exploratory model that contained several uncertainties in 
model parameter values.  The prospective observational cohort study was limited to critical 
care units, and so under sampled the population served by the diagnostic laboratory. This 
reduced the accuracy of the rates of nosocomial transmission and acquisition of MRSA. 
MRSA acquisition rates were varied in sensitivity analysis and did not change the cost-
effectiveness conclusions of the model. We used a mortality rate of 4.6% for hospital 
patients who develop MRSA infection, which represents a composite death rate from all-site 
infections. This was derived from a recent US study [10], and outcomes may differ in a UK 
setting. Furthermore, the case mix in this previous study may differ to our patient population; 
our patients had a very low rate of MRSA bacteraemia [16], which is associated with high 
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mortality [17]. Estimating the baseline QALY of an ‘average’ hospitalised patient was difficult 
because of the heterogeneity of the in-patient population as a whole, and we assumed that 
health-related quality of life was equal across patients upon entry to hospital. Sensitivity 
analysis did not indicate health related quality of life to be a key driver of the model results. It 
is also highly likely that we over-estimated the cost per case of MRSA infection as cost data 
were based on a study that assumed all patients would be treated within intensive care. 
These data were used because of the lack of other viable sources from a UK setting [12], 
but sensitivity analysis demonstrated that even at a minimal cost, sequencing would still be 
cost effective due to the costs saved through the reduction in colonised MRSA patients. 
 
A previously published comparative effectiveness review of screening for MRSA indicated 
insufficient evidence to determine the effectiveness of MRSA screening strategies [18]. This 
did not consider the effectiveness of screening combined with sequencing. A strength of our 
economic analysis is that it highlights specific data collection requirements of future 
prospective studies that evaluate the impact and cost-effectiveness of proactive MRSA 
sequencing.  
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Table 1: Model Inputs 
  
Patient classification parameters (%) 
Percentage of patients that undergo 
MRSA screening on admission 
87.5 Cambridge University Data 
Proportion of patients MRSA positive 
following screening 
1.1 Cambridge University Data 
Proportion of patients MRSA positive 
not screened 
1.1 
Assumed equal to above due to an 
absence of data  
Probability MRSA positive patient has 
symptomatic MRSA versus 
asymptomatic MRSA 
14.1 Cambridge University Data 
Effectiveness inputs (%) 
Probability of MRSA negative patient 
acquiring MRSA during their stay (CP) 
0.5 Assumption 
Reduction in MRSA acquisition due to 
genome sequencing  
90 Assumption 
Quality of life and mortality inputs 
Quality of life decrement associated 
with symptomatic MRSA 
0.35 US decision analytic model [19] 
Proportion of symptomatic MRSA 
patients that die before discharge due to 
MRSA infection (%) 
4.6 US cost study [10] 
Proportion of asymptomatic MRSA 
patients that die before discharge due to 
MRSA colonisation (%) 
0 Assumption 
Costs inputs (£) 
Cost per case of symptomatic MRSA 17,238 Kunori et al.  [12] 
Cost per case of asymptomatic MRSA 386.80  Canadian decision tree [11] 
Cost per genome sequenced 100 A descriptive study of WGS for MRSA [4] 
Cost per screen positive 8.19 UK model. Robotham et al. [14] 
Cost per screen negative 4.79 UK model. Robotham et al.[14] 
Cost per clinical sample 3.62 UK model. Robotham et al. [14] 
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Table 2: Clinical outcomes per annual hospitalised patient cohort (N=65,000) 
Clinical outcome WGS + CP CP 
Incremental 
Absolute Relative (%) 
Number of patients with MRSA sequenced 715 0 715 1.10 
Number of MRSA negative patients that 
acquire an MRSA infection† 
5 45 -41 -90 
Number of asymptomatic MRSA cases 614 863 -249 -28.8 
Number of symptomatic MRSA cases 101 142 -41 -28.8 
Number of MRSA related deaths 5 7 -2 -28.8 
 
WGS: Whole genome sequencing; CP: Current practice. 
†This refers to patients who were MRSA negative upon admission to hospital.  
Note: As these clinical outcomes are dependent upon assumptions within the model, we would not 
expect them to be equal to the to the results presented in the aforementioned prospective 
observational cohort study [6].  
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Table 3: Economic outcomes (per annual hospitalised cohort (N=65,000) 
 
Economic outcome - Costs WGS + CP (£)  CP (£) 
Incremental 
Absolute (£) Percentage (%) 
Genome sequencing costs  71,466 0.00 71,466 100 
MRSA related treatment costs 1,974,473 2,774,112 -799,639 -40 
Admission screening costs 274,462 274,462 0.00 0 
Outbreak investigation screening costs 39,108 39,083 24 0 
Clinical sampling costs 365 513 -148 -40 
Total Cost 2,359,873 3,088,170 -728,297 -31 
Economic outcome - QALYS WGS + CP CP Absolute Percentage (%) 
Total QALYS 64,965 64,950 14 0.02 
Incremental cost per QALY Less costly and more effective (Dominant) 
 
WGS: Whole genome sequencing; CP: Current practice. 
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Figure legends 
Figure 1: Model schematic 
 
Figure 2: Threshold graphs (cohort of 65,000 patients) 
Note: A negative incremental cost illustrates whole genome sequencing as cost saving.  For 
example, a -£1,000,000 incremental cost means whole genome sequencing is £1,000,000 
cheaper than current practice alone. 
 
Figure 3: Two-way sensitivity analysis (cohort of 65,000 patients) 
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Figure 1 
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Figure 2 
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Figure 3 
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